89 related articles for article (PubMed ID: 12841298)
1. Pulmonary hypertension in systemic sclerosis.
Denton CP; Black CM
Rheum Dis Clin North Am; 2003 May; 29(2):335-49, vii. PubMed ID: 12841298
[TBL] [Abstract][Full Text] [Related]
2. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again.
Bahi M; Li C; Wang G; Korman BD
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731946
[TBL] [Abstract][Full Text] [Related]
3. Systemic scleroderma: Review and updated approach and case description to addressing pulmonary arterial hypertension and idiopathic pulmonary fibrosis: A dual challenge in treatment.
Cueto-Robledo G; Tovar-Benitez D; Alfaro-Cruz A; Gonzalez-Hermosillo LM
Curr Probl Cardiol; 2024 Apr; 49(4):102404. PubMed ID: 38232920
[TBL] [Abstract][Full Text] [Related]
4. Advances in pathogenesis and treatment of systemic sclerosis.
Denton CP
Clin Med (Lond); 2016 Feb; 16(1):55-60. PubMed ID: 26833515
[TBL] [Abstract][Full Text] [Related]
5. Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell-based Therapy.
Wang ZH; Zhou Q
Am J Respir Crit Care Med; 2023 Mar; 207(6):795-796. PubMed ID: 36638561
[No Abstract] [Full Text] [Related]
6. Does reduced cathepsin activity contribute to skin and lung fibrosis in patients with systemic sclerosis and related disorders?
Garton M; Kelly C
Rheumatology (Oxford); 2024 Mar; 63(3):e81-e82. PubMed ID: 37831911
[No Abstract] [Full Text] [Related]
7. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A; Varga J
Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
[TBL] [Abstract][Full Text] [Related]
8. CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential.
Liu S; Liu C; Wang Q; Liu S; Min J
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830702
[TBL] [Abstract][Full Text] [Related]
9. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis.
Murdaca G; Lantieri F; Puppo F; Bezante GP; Balbi M
J Int Med Res; 2016 Sep; 44(1 suppl):85-89. PubMed ID: 27683147
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities in treating inflammation associated with pulmonary hypertension.
Voelkel NF; Tamosiuniene R; Nicolls MR
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):939-51. PubMed ID: 27096622
[TBL] [Abstract][Full Text] [Related]
12. Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.
Qian J; Tian W; Jiang X; Tamosiuniene R; Sung YK; Shuffle EM; Tu AB; Valenzuela A; Jiang S; Zamanian RT; Fiorentino DF; Voelkel NF; Peters-Golden M; Stenmark KR; Chung L; Rabinovitch M; Nicolls MR
Hypertension; 2015 Dec; 66(6):1227-1239. PubMed ID: 26558820
[TBL] [Abstract][Full Text] [Related]
13. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.
Jimenez SA
ISRN Rheumatol; 2013 Sep; 2013():835948. PubMed ID: 24175099
[TBL] [Abstract][Full Text] [Related]
14. Platelets in pulmonary hypertension: a causative role or a simple association?
Zanjani KS
Iran J Pediatr; 2012 Jun; 22(2):145-57. PubMed ID: 23056879
[TBL] [Abstract][Full Text] [Related]
15. Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.
Dimitroulas T; Mavrogeni S; Kitas GD
Nat Rev Rheumatol; 2012 Feb; 8(4):203-13. PubMed ID: 22310183
[TBL] [Abstract][Full Text] [Related]
16. Anti-cyclic citrullinated peptide antibodies in scleroderma patients.
Polimeni M; Feniman D; Skare TS; Nisihara RM
Clin Rheumatol; 2012 May; 31(5):877-80. PubMed ID: 22215120
[TBL] [Abstract][Full Text] [Related]
17. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.
Coral-Alvarado PX; Garces MF; Caminos JE; Iglesias-Gamarra A; Restrepo JF; Quintana G
Int J Rheumatol; 2010; 2010():. PubMed ID: 20871866
[TBL] [Abstract][Full Text] [Related]
18. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis.
Coral-Alvarado P; Quintana G; Garces MF; Cepeda LA; Caminos JE; Rondon F; Iglesias-Gamarra A; Restrepo JF
Rheumatol Int; 2009 Jul; 29(9):1017-24. PubMed ID: 19116719
[TBL] [Abstract][Full Text] [Related]
19. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.
Denton CP; Pope JE; Peter HH; Gabrielli A; Boonstra A; van den Hoogen FH; Riemekasten G; De Vita S; Morganti A; Dölberg M; Berkani O; Guillevin L;
Ann Rheum Dis; 2008 Sep; 67(9):1222-8. PubMed ID: 18055477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
